Daniel Schneiderman's most recent trade in Pasithea Therapeutics Corp was a trade of 1,129,323 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2026 | 1,129,323 | 1,129,323 | - | - | Stock Option (right to buy) | |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.75 per share. | 28 Nov 2025 | 26,667 | 26,667 | - | 0.7 | 20,000 | Common Stock |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2025 | 317,266 | 317,266 | - | - | Stock Option (right to buy) | |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 5,927 | 5,927 | - | - | Stock Option (right to buy) | |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 5,927 | 5,927 | - | - | Stock Option (right to buy) | |
| Pasithea Therapeutics Corp | Daniel Schneiderman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2022 | 300,000 | 300,000 | - | - | Stock Option (to acquire Common Stock) | |
| First Wave BioPharma Inc | Daniel Schneiderman | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock option (right to buy) |